What is the difference between AICAR and GLP-1 (7-37)?

AICAR: Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercis… GLP-1 (7-37): Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Is AICAR FDA approved?

AICAR is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is AICAR administered in research settings?

In research settings, AICAR is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AICAR vs GLP-1 (7-37)

Peptide Comparison

AICAR vs GLP-1 (7-37)

Name: AICAR vs GLP-1 (7-37) — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Metabolic peptides.

AICAR

Acadesine

PerformanceInvestigationalResearch Only

3 providers listed

Full AICAR profile →

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Bottom line

AICAR carries stronger published evidence (RCT, 12 key studies) than GLP-1 (7-37) (RCT, 2); both are research compounds.

Quick Verdict

AICAR

Evidence

Clinical

GLP-1 (7-37)

Evidence

Emerging Clinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	AICAR
Further along in FDA review	AICAR
More provider options (3 vs 33)	GLP-1 (7-37)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AICAR

GLP-1 (7-37)

Mechanism Family

Metabolic

Half-life

—

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

Availability

Research Only

Providers

3 listed

33 listed

Research Evidence

AICAR

ClinicalRCT · 12 key studies · most recent 2026

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Research Citations

AICAR

Review2026 · Cells

Targeting AMPK Networks for Male Reproductive Health: Mechanisms and Emerging Therapies.

Cohort2026 · Biochem Biophys Res Commun

Thapsigargin-induced autophagic flux impairment and inflammation are potentiated by CLN3 deficiency and allev…

Cohort2026 · Free Radic Biol Med

The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al…

Cohort2026 · Chin J Integr Med

Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway.

+8 more

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

About AICAR

Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.

Research Areas

endurancefat oxidationmitochondrial biogenesisAMPK activation

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AICAR

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Price (per mg)

AICAR

$0.90/mg

$0.64 – $1.11 range

12 vendors

View price index →Find providers →

GLP-1 (7-37)

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

AICAR

3 listed

Browse directory →

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AICAR vs GLP-1 (7-37) — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/aicar/glp-1-7-37

https://peptidebase.io/peptides/compare/aicar/glp-1-7-37 Methodology License Download JSON Download CSV